Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
New Jersey, USA-based cancer specialist Bristol-Myers Squibb has announced positive data in lung cancer for its immuno-oncology combination, Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab). 22 October 2019
Biotechnology
US biotech major Biogen saw its shares rocket more than 41% to $315.74 in pre-market trading, after, along with partner Eisai, today announced that, following consulting with the US Food and Drug Administration, Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer’s disease (AD), which has previously seen disappointing clinical results. 22 October 2019
Biotechnology
Japanese drugmaker Takeda Pharmaceutical has announced data from the EVOLVE study, in an oral presentation at UEG Week 2019 in Barcelona. 21 October 2019
Biotechnology
Gene-editing start-up CRISPR Therapeutics and German pharma major Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture set up in 2016 between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. 21 October 2019
Biotechnology
GlaxoSmithKline will divest its travel vaccine brands, acquired from Novartis in 2015 as part of the acquisition of its vaccines business, to Denmark’s Bavarian Nordic (OTC: BVNRY). 21 October 2019
Biotechnology
UK biotech start-up Achilles Therapeutics today announced the appointment of Beverley Carr as chief business officer, with effect from November 4, 2019. 21 October 2019
Biotechnology
The Phase III IMbrave150 study, evaluating Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically-significant and clinically-meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib. 21 October 2019
Biotechnology
The US Food and Drug Administration has approved Ultomiris (ravulizumab-cwvz) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) for adult and pediatric (one month of age and older) patients. 21 October 2019
Biotechnology
Patient advocacy groups HPV Action and the Teenage Cancer Trust have said that a new program in the UK, offering HPV vaccines for boys, is insufficient. 18 October 2019
Biotechnology
Hong Kong-based artificial intelligence specialist Great Bay Bio has launched a strategic cooperation with Boji Medical to jointly develop GBB101, a new long-acting injectable biologic. 18 October 2019
Biotechnology
Johnson & Johnson’s pharma arm, Janssen, has announced new long-term data from the open-label period of the Phase III VOYAGE 1 clinical trial of Tremfya (guselkumab). 18 October 2019
Biotechnology
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications. 18 October 2019
Biotechnology
The USA’s Biotechnology Innovation Organization’s (BIO), after the Congressional Budget Office (CBO) released an analysis confirming that Bill HR 3 will lead to fewer new medicines for patients, issued its own warning. 18 October 2019
Biotechnology
Shares of Israel’s RedHill Biopharma leapt 10% pre-market and were still up 5% at $6.48 inn late morning US trading after the company announced an exclusive license agreement with Cosmo Pharmaceuticals for US rights to Aemcolo (rifamycin) for traveler’s diarrhea and a simultaneous private investment by Cosmo. 17 October 2019
Biotechnology
Stealth BioTherapeutics, a US biotech focused on diseases involving mitochondrial dysfunction, has announced new data on its lead product. 17 October 2019
Biotechnology
Shares in Belgian drugmaker UCB were buoyed by positive Phase III data for the firm’s key pipeline candidate, bimekizumab, on Thursday. 17 October 2019
Biotechnology
Swiss company Lonza and Mesoblast have agreed a commercial manufacturing deal for the Australian biotech’s lead allogeneic cell therapy, remestemcel-L. 17 October 2019
Biotechnology
Eli Lilly has announced negative top-line results from the Phase III SEQUOIA trial, evaluating pegilodecakin plus Folfox (folinic acid, 5-FU, oxaliplatin) as a therapy for certain people with pancreatic cancer. 16 October 2019
Biotechnology
US biotech Incyte Corp today announced positive results from the Novartis -sponsored pivotal Phase III REACH2 study evaluating Jakafi (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease (GVHD). 16 October 2019
Biotechnology
Paris-based drugmaker Ipsen has inked a deal with the USA’s Blueprint Medicines for the development and commercialization of the investigational ALK2 inhibitor BLU-782. 16 October 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze